Insights - Just a day after Retrophin (RTRX) announced a $100 million financing the U.S. FDA has approved its Cholbam (cholic acid) for pediatric and adult patients with bile … Continue Reading
Read nowInsights - The big news this weekend out of the American College of Cardiology's annual scientific session was the comparison of long-term outcomes for two new (and competing) drugs targeting cholesterol,
Read nowResearch - Synergy Pharmaceuticals (SGYP) will shortly report phase 3 data from two large trials of lead candidate plecanatide in Chronic Constipation.
PremiumInsights - Zogenix (ZGNX) is divesting of its lead FDA-approved product, the painkiller Zohydro, for $100 million ($30 million in cash up front) and almost $300 million in potential milestone payments. As much as the cash and milestone potential are important to Zogenix, which is re-positioning itself as a pipeline story, more important is that Zogenix is cutting loose the albatross around its neck for the last year and a half.
Read nowResearch - SAGE Therapeutics (SAGE) and Marinus Pharmaceuticals (MRNS)are innovators in a class of molecules known as neurosteroids and both target epilepsy initially.
PremiumInsights - In yet another uninspiring piece of news for AcelRx (ACRX), the company reported on Monday that the FDA wants another clinical study of the company’s Zalviso patient-controlled analgesic … Continue Reading
Read nowResearch - Conatus Pharmaceuticals' (CNAT) CMO, Dr. Gary Burgess, tendered his resignation on Thursday. Here's why investors should take note.
Premium
